title: Dansyl-PQRamide, a possible neuropeptide FF receptor antagonist, induces conditioned place preference.
abstract: Neuropeptide FF (NPFF) is an endogenous anti-opioid peptide. NPFF could potentiate the naloxone-precipitated morphine withdrawal syndromes in morphine-dependent rats, indicating the possible involvement of the endogenous NPFF system in opioid analgesia and dependence. The present study was performed to examine the effects of dansyl-PQRamide (dns-PQRa), a putative NPFF antagonist, on conditioned place preference (CPP), in addition, its interaction with the opioid system. Two CPP experiments were conducted. First, rats were treated with dns-PQRa (4-13 mg/kg, i.p.) and paired with the non-preferred compartment while the vehicle was paired with the preferred compartment. Second, similar to experiment 1 except naloxone (1 mg/kg, i.p.) was given 10 min prior to each dns-PQRa administration. The post-drug place preference was examined after 4 alternative pairings. Another group of animals after repetitive dns-PQRa treatments were analyzed for levels of neurotransmitters in discrete brain areas. Dns-PQRa (4-13 mg/kg, i.p.) induced a significant dose-dependent CPP. The dns-PQRa-induced CPP was completely blocked by pretreatment with 1 mg/kg i.p. naloxone, while naloxone alone did not induce any place aversion. The chronic dns-PQRa-treated (13 mg/kg, i.p., b.i.d.) rats caused a significant increase in 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in the olfactory tubercle compared to the vehicle-treated controls. There was also an increase in the turnover of serotonin in the olfactory tubercle, nucleus accumbens and medial prefrontal cortex. These results suggest that blockade of the NPFF system produces rewarding, possibly via an inhibition of the anti-opioid action of NPFF. These results also reveal a close relationship between NPFF, drug rewarding and the dopaminergic and serotoninergic neurons in the mesolimbic system.
authors.affiliation: Department of Pharmacology, National Defense Medical Center, Nei-Hu 114, Taipei, Taiwan, ROC. eyh58@ndmctsgh.edu
authors.forename: E Y K
authors.initials: EY
authors.lastname: Huang
authors.forename: J Y
authors.initials: JY
authors.lastname: Li
authors.forename: C H
authors.initials: CH
authors.lastname: Wong
authors.forename: P P C
authors.initials: PP
authors.lastname: Tan
authors.forename: J C
authors.initials: JC
authors.lastname: Chen
mesh_terms: D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D003213:Conditioning, Psychological / Q000187:drug effects; D004347:Drug Interactions; D018698:Glutamic Acid / Q000378:metabolism; D008297:Male; D023421:Models, Animal; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology*; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D009292:Narcotic Antagonists; D009479:Neuropeptides; D018013:Receptors, Neuropeptide; C402061:dansyl-prolyl-glutaminyl-argininamide; C083929:neuropeptide FF receptor; D001224:Aspartic Acid; D009270:Naloxone; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid